Brad Giarrusso, MD
Internal Medicine · Baker, LANPI 1104844455
Payments from drug & device makers
Across 265 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$586
- Novo Nordisk$499
- Pfizer$328
- Boehringer Ingelheim$300
- Bayer$291
- Merck$275
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,421100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 42 | $586 |
| Novo Nordisk | 31 | $499 |
| Pfizer | 25 | $328 |
| Boehringer Ingelheim | 12 | $300 |
| Bayer | 15 | $291 |
| Merck | 15 | $275 |
| Johnson & Johnson | 12 | $273 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $263 |
| AbbVie(2 entities) | 15 | $233 |
| Amgen | 10 | $160 |
| Supernus Pharmaceuticals, Inc. | 8 | $155 |
| Kowa Pharmaceuticals America, Inc. | 9 | $154 |
| GSK | 8 | $134 |
| Teva Pharmaceuticals USA, Inc. | 11 | $131 |
| AstraZeneca | 8 | $128 |
| Abbott | 5 | $91 |
| Xeris Pharmaceuticals, Inc. | 4 | $57 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Sanofi Pasteur Inc. | 2 | $36 |
| Adlon Therapeutics L.p. | 2 | $36 |
| Ironshore Pharmaceuticals Inc. | 2 | $35 |
| Novartis | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Shire North American Group Inc | 2 | $25 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Neos Therapeutics, LP | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,421 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 133 | $132,036 |
| OzempicSemaglutide | 112 | $128,570 |
| MounjaroTirzepatide | 49 | $64,534 |
| EliquisApixaban | 69 | $58,605 |
| TrulicityDulaglutide | 28 | $35,013 |
| RybelsusSemaglutide | 17 | $26,122 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $24,715 |
| EntrestoSacubitril/Valsartan | 26 | $24,354 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,366 |
| Spiriva RespimatTiotropium Bromide | 18 | $13,485 |
| XareltoRivaroxaban | 13 | $13,322 |
| JanuviaSitagliptin Phosphate | 17 | $13,261 |
| TrintellixVortioxetine Hydrobromide | 13 | $10,641 |
| LinzessLinaclotide | 13 | $6,928 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $6,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $499 | $154,692129 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $300 | $145,521151 claims |
| Lilly USA, LLCMounjaro, Trulicity | $586 | $99,54777 claims |
| PfizerEliquis | $328 | $58,60569 claims |
| NovartisEntresto | $31 | $24,35426 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $134 | $22,52133 claims |
| Johnson & JohnsonXarelto | $273 | $13,32213 claims |
| MerckJanuvia | $275 | $13,26117 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $263 | $10,64113 claims |
| AbbVieLinzess, Synthroid | $233 | $8,30157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Baker
- Ernest ThompsonBaker$2.1M
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.